Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)
|癌症的個體化醫療:醫生層級主要的促進要素、課題的評估 (EU5個國家) Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)|
|出版日期: 2015年05月01日||內容資訊: 英文||
本報告以對EU5個國家(法國、德國、西班牙、義大利及英國) 150名癌症專門醫生的調查結果為基礎，提供 癌症專門醫生考慮的個體化醫療領域中的重要問題，課題及機會相關考察，癌症專門醫生將來打算引進何種個體化醫療的調查。
Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists.
Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5) is based on survey results from 150 oncologists (104 medical oncologists and 46 haematologist-oncologists) in France, Germany, Spain, Italy and the UKand offers insights on what oncologists believe are the critical issues, challenges and opportunities within the personalised medicines space, and how oncologists intend to adopt personalised medicine in the future.
A great deal of anticipation and expectation surrounds personalised medicine. While there have been some notable successes, the promise of personalised medicine - right medicine, right patient, right time - has failed to materialise in many disease areas where a personalised approach could drive better patient outcomes. Concerns amongst key stakeholder groups remain, particularly in relation to development, access and implementation of personalised healthcare strategies.
This survey provides EU5 physician insights into personalised medicine within the oncology setting. By understanding what oncologists in the major markets in Europe think about the key challenges, opportunities and concerns, companies operating in the oncology market and seeking to leverage personalised medicine for their products can gain a deep understanding of what's needed to drive long-term commercial success.
Filled with charts and up-to-the-minute survey analysis, this report offers: